This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Urological System Disease Animal Model Development Service
Introduction
BioVenic's end-to-end preclinical services accelerate your research journey. BioVenic offers comprehensive solutions in diverse urological animal model construction, robust model validation techniques, and complete downstream sample analysis. Partner with us to achieve high-quality models and streamline your non-GLP studies.
BioVenic Urological System Disease Animal Model Development Services
Urological System Disease Animal Model Development
From simple induced models to intricate genetically modified lines, BioVenic specializes in creating a broad range of urological and nephrological animal models. We are excellent at creating customized models that go beyond standard models (such as Unilateral Ureteral Obstruction (UUO) for renal fibrosis and STZ-induced diabetic nephropathy). Utilizing a variety of induction techniques-surgical, pharmacological, chemical, and genetic-to perfectly match your research goals is BioVenic's edge.
Urological System Disease Animal Model Validation
Thorough validation is necessary for successful model construction in order to guarantee that the animal appropriately represents the target pathophysiology. To verify the success of the model, BioVenic provides thorough characterization and validation services. Common validation methods include:
- Physiological & Functional Assays: Measuring bladder capacity, voiding frequency, intravesical pressure (e.g., using Cystometry in BOO models), and monitoring blood pressure.
- Biochemical Analysis: Detecting key biomarkers in serum and urine (e.g., BUN, Creatinine, Urine Protein/Albumin Ratio for kidney injury).
- Pathological Assessment: Performing Histopathology (H&E, Masson's Trichrome, PAS staining) on kidney, bladder, and prostate tissues to quantify fibrosis, inflammation, and cellular changes.
Urological System Disease Animal Model Sample Collection and Processing Services
BioVenic provides expert, precise collection and processing of biological samples crucial for subsequent analysis or direct client transfer. This includes:
Tissue Samples: Collecting fresh, frozen, or fixed urological tissues (kidney, bladder, prostate, etc.).
Biofluids: Collecting blood (serum/plasma), urine, and cerebrospinal fluid.
Cell Isolates: Making primary cell cultures from certain organs.
Downstream Experimental Research on Urological System Disease Animal Models
Use our experience to carry out a variety of non-GLP preclinical investigations on the created animal models:
Pharmacodynamic (PD) Studies: Evaluating lead compounds' biological effects and target engagement.
Safety and Efficacy Studies: Assessing possible medicinal substances or tools.
Mechanism of Action Studies (MoA): Utilizing Western blot, qPCR, and ELISA to explore signaling pathways.
Advanced Imaging: Employing techniques for in vivo imaging and structural analysis.
Explore BioVenic's investigative modalities:
- Animal Behavioral Analysis
- Animal Histopathology Service
- Preclinical Animal Pharmacodynamics (PD) Study
- Preclinical Animal Pharmacokinetics (PK) Study
- Animal Cell Biology Service
- Animal lmaging Service
BioVenic's animal urological system disease model related services include:
- Genome-edited Animal Model Development
- Chemically-induced Animal Model Development
- Diet-induced Animal Model Development
- Surgically-induced Animal Model Development
Development Workflow for a Urological System Disease Animal Model
Urological System Disease Animal Model Research Areas Overview
Table. 1 Common Urological System Disease Animal Models and Research Areas
| Disease Model | Modeling Method/Mechanism | Animal Species | Research Application Areas |
|---|---|---|---|
| Diabetic Nephropathy (DN) | Streptozotocin (STZ) induction (Type 1 DM, sometimes with high-fat diet for Type 2); Spontaneous models (NOD mouse, KK-Ay mouse, db/db mouse) | Rat (SD, WISTAR), Mouse (NOD, KK-Ay, db/db) | Studying pathogenesis, screening drugs for diabetic complications, assessing anti-proteinuric and anti-fibrotic agents. |
| Chronic Kidney Disease (CKD) / Chronic Renal Failure (CRF) | Subtotal Nephrectomy (5/6 or 5/8 removal); Adenine-induced; Chronic anti-Thy1 antibody nephritis; UUO (Unilateral Ureteral Obstruction) for renal fibrosis/CRF progression. | Rat (SD, WISTAR), Mouse | Researching CKD progression, renal fibrosis, uremia, drug efficacy against renal insufficiency and anemia. |
| Acute Kidney Injury (AKI) / Acute Renal Failure (ARF) | Renal Ischemia-Reperfusion Injury (RIRI) (bilateral renal artery clamping); Nephrotoxic agents (e.g., Cisplatin, Gentamicin, HgCl2, Glycerol); Lipopolysaccharide (LPS) induction. | Rat, Mouse, Rabbit, Guinea Pig, Dog | Investigating mechanisms of AKI (e.g., surgery-related, transplant), testing renoprotective agents. |
| Glomerulonephritis (GN) | Heymann Nephritis (Fraction 1A antigen induction for Membranous Nephropathy); IgA Nephropathy (e.g., BSA-LPS-CCl4 method, immune complex induction); Chronic anti-Thy1 Antibody Nephritis (for mesangial proliferative GN). | Rat (SD), Mouse (ICR, BALB/C) | Studying autoimmune mechanisms, inflammation, and evaluating treatments for specific types of GN. |
| Nephrotic Syndrome (NS) | Doxorubicin (ADR)/Adriamycin induction; Puromycin Aminonucleoside (PAN) induction (Diamond method for minimal change/FSGS, Eddy method for reversible interstitial fibrosis). | Rat (SD, WISTAR), Mouse (BALB/C) | Researching podocyte injury, proteinuria, focal segmental glomerulosclerosis (FSGS), and testing immunosuppressants. |
| Renal Fibrosis (RF) / Interstitial Fibrosis | Unilateral Ureteral Obstruction (UUO); 5/6 Nephrectomy; Adenine-induced; Gentamicin or Cyclosporine A (CsA) induction. | Rat (SD), Mouse | Studying mechanisms of tubulointerstitial fibrosis, evaluating anti-fibrotic therapies. |
| Urolithiasis (Kidney Stones) | Ethylene Glycol and Ammonium Chloride (EG + AC) administration; Glyoxalate injection. | Rat (SD), Mouse | Researching stone formation mechanisms, evaluating litholytic and preventative drugs. |
| Pyelonephritis (Acute) | Surgical procedure combined with bacterial infection (e.g., E. coli) and/or ureteral ligation. | Rat, Mouse, Rabbit | Studying ascending urinary tract infection, inflammation, and testing antibiotics. |
| Bladder Diseases | Cystitis (E. coli infection); Bladder Outlet Obstruction (BOO) (ligation of bladder neck). | Rat, Mouse | Investigating lower urinary tract infections, voiding dysfunction, and benign prostatic hyperplasia (BPH) consequences. |
| Prostatic Hyperplasia/Disease | Testosterone propionate (TP) subcutaneous injection (for BPH). | Rat (SD) | Evaluating treatments for BPH, studying endocrine-related prostate changes. |
| Genetic Models | Various genetically modified mice (e.g., for IgA Nephritis, Renal Cancer, Cystic Kidney). | Mouse | Advanced research into specific genetic pathways, rare diseases, and targeted drug screening. |
Advantages of BioVenic Urological System Disease Animal Model Development Service
Diverse Existing Urological Models
To choose the best animal model and strain (mouse, rat, rabbit, pig) for your particular study topic, BioVenic employs a wide range of modeling methodologies, including genetic, nutritional, chemical, and surgical.
Project Customization
BioVenic creates a customized protocol based on your initial data and experimental objectives. To guarantee successful results and conclusions that are supported by science, we combine the best model with an optimum experimental design.
Robust Detection Platforms
Beyond model construction, our extensive capabilities include comprehensive animal biochemical indicator and pathological detection platforms, essential for rigorous model validation and sample analysis.
Seamless One-Stop Service
BioVenic offers an integrated workflow from initial model consultation and construction through in vivo study execution and final data analysis. Your research schedule is accelerated and logistical complexity is reduced with this consolidated solution.
Case Study: Adenine-Induced Renal Fibrosis & Efficacy Evaluation
Our platform offers a high-fidelity chronic kidney disease (CKD) model via a standardized four-week 0.2% adenine-enriched diet protocol, delivering consistent progressive renal impairment. To ensure rigorous modeling validation, we provide comprehensive biochemical profiling of blood urea nitrogen (BUN) and serum creatinine levels, integrated with histological quantification via Masson's trichrome staining to assess tubular atrophy and collagen deposition. This robust system is specifically optimized for evaluating the pharmacological mechanisms of therapeutic candidates. By combining standardized induction with deep molecular analysis, we provide the precise data necessary to validate the anti-fibrotic efficacy of your compounds and accelerate their repositioning or development for chronic renal diseases.
Fig. 1 Metformin attenuates adenine-induced renal injury1
FAQs
Q: How do you make sure the models you create are suitable for my research?
A: To ensure the model appropriately represents the intended pathophysiology, we conduct a thorough validation utilizing a combination of functional assays (such as cystometry), biochemical markers (such as blood Cr/BUN), and histological examination.
Q: For my test article, are you able to manage personalized dosing schedules and routes?
A: In accordance with your particular protocol needs, our skilled in vivo staff is competent in all typical administration routes, including oral gavage, subcutaneous, intravenous, intraperitoneal, and local organ injections.
Q: Do you provide samples for external analysis?
A: Definitely. We provide professional sample collection and processing (frozen, fixed tissues, biofluids), which can be sent straight to your lab or to outside partners for specialized testing.
Contact Us
BioVenic's expertise in Urological System Disease Animal Model Development is designed to be your catalyst for non-GLP preclinical success. We provide the accuracy, personalization, and strong validation required to effectively forward your research initiatives. contact us today to discuss your project needs and request a confidential quote!
Reference
- Yi, Hao, et al. "Metformin attenuates renal fibrosis in a mouse model of adenine-induced renal injury through inhibiting TGF-β1 signaling pathways." Frontiers in Cell and Developmental Biology 9 (2021): 603802. https://doi.org/10.3389/fcell.2021.603802. Distributed under Open Access license CC BY 4.0. Without modification.